Endorsed by

Global Gynecologic Oncology Hub
Translational Research, Early Discovery, and the Shaping of Future Policy

Palace of Parliament
March 26-28, 2026

mask
Scientific program
Download Final Program (PDF)

March 26 - NICOLAE IORGA HALL - Translational Research Foundations & Drug Development Pathways

09:00 - 09:15
Opening

Welcome and Opening Remarks

Viorel Jinga, Cătălina Poiana, Dana Lucia Stanculeanu, Elena-Ioana Braicu, Jalid Sehouli, Gheorghe Peltecu
09:15 - 10:25
Key Session

Translational Research: From Concept to Clinical Application

Chairs Ioana Berindan Neagoe, Delia Mezzanzanica
  • 09:15 - 09:35 The Role of microRNAs in Cancer Development and Therapeutic Targeting George Calin
  • 09:35 - 10:00 Microenvironmental Changes as Therapeutic Targets in Early Ovarian Cancer Genesis Mihnea Dragomir
  • 10:00 - 10:10 Discussion
  • 10:10 - 10:25 Ewo Pharma Symposium: Second-Line Options Expand Beyond Chemotherapy in Endometrial Cancer Dana Stanculeanu
10:25 - 10:45
Break

Coffee Break & Industry Exhibition

10:45 - 12:45
Scientific Session

Liquid Biopsies: From Research Tool to Clinical Decision-Making

Chairs Delia Mezzanzanica, Irina Cazacu-Croitoru
  • 10:45 - 11:05 Circulating Tumor DNA: Clinical Validation and Implementation Victor Velculescu
  • 11:05 - 11:25 Transcriptional Changes Associated with Tumor Presence Detected in Liquid Biopsy Ioana Berindan Neagoe
  • 11:25 - 11:45 Translating Liquid Biopsy into Real-World Clinical Decisions Adelina Silvana Gheorghe
  • 11:45 - 12:00 Discussion
  • 12:00 - 12:45 MSD Symposium Cervical Cancer Across the Care Continuum: From Prevention to Treatment Dana Lucia Stanculeanu, Gheorghe Peltecu, Serban Nastasia
12:45 - 13:30
Break

Lunch Break

13:30 - 15:15
Scientific Session

Drug Development Journeys: Phase I to Market

Chairs Elena-Ioana Braicu, Dan Jinga, Dana-Lucia Stanculeanu
  • 13:30 - 13:50 PARP Inhibitors: From First-in-Human Studies to Pan-Gynecologic Applications Jonathan Ledermann
  • 13:50 - 14:10 Bevacizumab Across Gynecologic Cancers: From Phase I to Standard of Care Nicoletta Colombo
  • 14:10 - 14:30 Checkpoint Inhibitors: Phase I Discoveries to Gynecologic Oncology Approvals Phillipp Harter
  • 14:30 - 14:45 Discussion
  • 14:45 - 15:00 Pharma& symposium - New horizons in PARPi for patients with Advanced Ovarian Cancer Elena-Ioana Braicu
  • 15:00 - 15:15 Stada Symposium - Bone Health Matters: Optimizing the Management of Bone Metastases with Zvogra (denosumab) Dragos Median
15:15 - 15:25
Break

Coffee Break & Industry Exhibition

15:25 - 16:35
Scientific Session

Biomarker Development and Cross-Sector Learning

Chairs Dragos Median, Mircea Dediu
  • 15:25 - 15:45 Are Biomarkers Valid or Is Our Approach Incorrect? The HER2 vs. FRA Story Delia Mezzanzanica
  • 15:45 - 16:05 HRD Testing: From Discovery to Clinical Implementation Daniela Zob
  • 16:05 - 16:25 HER2-Targeted Therapy: Lessons from Breast Cancer for Gynecologic Oncology Dennis Slamon
  • 16:25 - 16:35 Discussion
16:35 - 18:05
Symposium

Industry-Sponsored Symposium

  • 16:35 - 16:55 BMS Symposium- Medical Hub
    Where Legacy Meets Innovation: From Classic Biomarkers to New Therapeutic Mechanisms in TNBC Mircea Dediu
  • 16:55 - 17:35 BMS Symposium- Medical Hub
    Biomarkers Testing Across Pathologies: From Diagnosis to Treatment Decisions Dana Lucia Stanculeanu, Claudia Burz
  • 17:35 - 18:05 Industry Symposium  Gilead: Bridging guidelines and practice: Expert consensus on mTNBC and HR+/HER2– in Romania Dragos Median
18:05 - 18:15
Wrap-Up

Day 1 Summary and Key Insights 

March 27 - NICOLAE IORGA HALL - Resistance Mechanisms & Therapeutic Evolution

08:45 - 09:10
Scientific Session

Welcome address by the Minister of Health and overview of Romania’s cancer care initiatives

09:00 - 10:25
Scientific Session

Understanding and Overcoming Resistance

Chairs Cornelia Nitipir, Gabriel Kacso
  • 09:00 - 09:20 Years of Insights into Platinum-Based Resistance: From Discovery to Clinical Management James Brenton
  • 09:20 - 09:40 PARP Inhibitor Resistance: Laboratory Discovery to Clinical Solutions Daniela Matei
  • 09:40 - 09:55 Discussion
  • 09:55 - 10:25 Eli Lilly Symposium: What Does Platinum Sensitivity Mean After PARP Inhibitors in Ovarian Cancer? Elena Ioana Braicu
10:25 - 10:40
Break

Coffee Break & Industry Exhibition

10:40 - 10:55
Scientific session

  • 10:40 - 10:55 Translating Health Science for the Public Daniel Nagel
10:55 - 12:35

Industry-Sponsored Symposium

  • 10:55 - 11:55 Educational session organized with the support of Abbvie - Redefining Possibilities:Mirvetuximab Soravtansine and the PROC challenge Jalid Sehouli, Mihnea Dragomir, Constantin Volovat, E. Ioana Braicu, Dana Stanculeanu, Dragos Median
  • 11:55 - 12:35 AstraZeneca Symposium: Endometrial Cancer Treatment in the Molecular Era Nicoletta Colombo, Elena. Ioana Braicu
12:35 - 13:10
Break

Lunch Break

13:10 - 14:10
Conferral Ceremony

Conferral Ceremony

  • 13:10 - 14:10 Conferral Ceremony of the Title Doctor Honoris Causa of the Carol Davila University of Medicine and Pharmacy to Prof. Dr. Dennis Slamon Prof. Dr. Viorel Jinga
14:10 - 15:40
Scientific Session

Next-Generation Therapeutics

Chairs Gottfied Koneczny, Dana-Lucia Stanculeanu, Mircea Dediu
  • 14:10 - 14:30 CAR-T Therapy for Solid Tumors: Early Phase Progress? Oliver Dorigo
  • 14:30 - 14:50 Bispecific Antibodies: Principles, Targets and Limitations Frederik Marmé 
  • 14:50 - 15:10 AI-Designed Therapeutics: Predicting Patient Response Christiane Hoeper
  • 15:10 - 15:30 Diversity in Early Clinical Trials: Patient Perspectives Jalid Sehouli
  • 15:30 - 15:40 Discussion
15:40 - 15:50
Break

Coffee Break

15:50 - 16:50
Symposium

Industry Symposium

  • 15:50 - 16:50 AstraZeneca Symposium: Bridging Evidence and Practice in Breast Cancer. Connecting the dots to redefine clinical impact Dana Lucia Stanculeanu, Cornelia Nitipir, Dragos Median
16:50 - 18:25
Scientific Session

Treatment Optimization and Patient-Centered Care

Chairs Michael Birrer, Radu Vidra
  • 16:50 - 17:10 Optimizing Treatment Sequences in Endometrial Cancer Michael Birrer
  • 17:10 - 17:30 Optimizing Treatment Sequences in Ovarian Cancer Robert Coleman
  • 17:30 - 17:50 Mismatch Repair Alterations in Gynecologic Cancers: When Does It Change Clinical Management? Radu Vidra
  • 17:50 - 18:10 Merck Symposium: Fertility preservation for medical reasons Cezara Bucur
  • 18:10 - 18:25 REGENERON | MEDISON Symposium: Quality of Life and Survival in Recurrent or Metastatic Cervical Cancer: Insights from EMPOWER Cervical 1 Dragos Median

March 28 - NICOLAE IORGA HALL -ADC Innovation, Global Perspectives & Hub Development

08:30 - 09:45
Scientific Session

Antibody-Drug Conjugates: From Design to Clinical Success

Chairs Sven Mahner, Daniela Zob, Claudia Burz 
  • 08:30 - 08:50 ADC Design Principles: From Biomarker Identification to Payload Selection Gottfried Konecny
  • 08:50 - 09:10 Mechanisms of Resistance to ADCs: Laboratory Insights to Clinical Management? Toon Van Gorp
  • 09:10 - 09:30 ADC Combination Strategies: Rational Design and Clinical Implementation Nicum Shibani
  • 09:30 - 09:45 Discussion
09:45 - 10:30
Symposium

Industry-Sponsored Symposium

  • 09:45 - 10:30 Tubulis Symposium: Novel linkers to unlock the therapeutic potential of ADCs in ovarian cancer and beyond Jonas Helma-Smets
10:30 - 11:00
Break

Coffee Break & Industry Exhibition

11:00 - 12:30
Scientific Session

Surgery vs. chemotherapy. When to Cut, When to Treat, and When to Turn Up the Heat

Chairs Alexandru Blidaru, Gabriel Dimofte
  • 11:00 - 11:20 Beyond the OR: Pitfalls and Successes in Surgical Trials?Insights from LION & TRUST. Sven Mahner
  • 11:20 - 11:40 HIPEC vs. Alternatives: IP Chemo, PIPAC, or Systemic-Only? Octav Ginghina
  • 11:40 - 12:00 TRUST results implementation in Romania Dan Eniu
  • 12:00 - 12:20 Role of Surgery in Relapsed Ovarian Cancer Gheorghe Peltecu
  • 12:20 - 12:30 Discussion
12:30 - 13:10
Break

Lunch Break

13:10 - 14:45
Key Session

Establishing the Global Gynecologic Oncology Innovation Hub

  • 13:10 - 13:30 Clinical Trials in Romania: Building Regional Hub Capacity Volovat Constantin
  • 13:30 - 13:50 Eastern Europe as an Innovation Hub for Clinical Trials: Opportunities and Challenges Benjamin Willan
  • 13:50 - 14:10 Delivering Excellence in Clinical Trials: Romania’s Oncology Enrollment Success – An Industry Perspective Alina Codrescu
  • 14:10 - 14:30 Bridging Clinical Research: From Academic Oncology to Industry and Vice Versa Mihaela Cristea
  • 14:30 - 14:45 Panel Discussion and Audience Q&A
14:45 - 15:15
Symposium

Industry-Sponsored Symposium

  • 14:45 - 15:00 Industry Symposium Pfizer: Comparative Real World Evidence on CDK4/6 Inhibitors: Insights From the P VERIFY Study on OS and rwPFS data Dana Lucia Stanculeanu
  • 15:00 - 15:15 Industry Symposium Pfizer: IBRANCE in Routine Practice: Updated Insights from IOB Oana Trifanescu
15:15 - 15:30
Break

Coffee Break & Industry Exhibition

15:30 - 16:05
Symposium

Industry-Sponsored Symposium

  • 15:30 - 15:50 Industry Symposium Baxter: Optimizing Treatment with Liposomal Doxorubicin: Lessons from Ovarian and Breast Cancer Cases Adelina Gheorghe
  • 15:50 - 16:05 Industry Symposium Amgen: When Tumors Seem Immunologically Silent, Innovation Emerges: DLL3-Directed Bispecific Therapy Mircea Dediu
16:05 - 17:05
Round Table

Roundtable Discussion: Launching the Global Gynecologic Oncology Innovation Hub

Moderators Adelina Gheorghe, Elena Iovanescu, Elena Ioana Braicu
  • 16:05 - 17:05 Panelists, Sevda Memet,  Mihaela Cristea, Andrei Baciu,  Jalid Sehouli, George Calin,  Octavian Andronic
17:30 - 17:45
Closing

Closing Remarks

Jalid Sehouli, Dana-Lucia Stanculeanu, Elena-Ioana Braicu